Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina

Circulation

Volumn 98, Issue 15, 1998, Pages 1575-1582

  Hirsh, Jack ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG FORMULATION; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; META ANALYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

EID: 0032514663     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.15.1575     Document Type: Review

References (44)

1. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337: 688-698.
2. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
3. Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochem Biophys Acta. 1985;845:196-203.
4. Young E, Prins MH, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67(6):639-643.
5. Levine M, Hirsh J, Gent M, Turpie AGG, Cruickshank M, Weitz JI, Anderson DR, Johnston M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
6. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
7. a by factor V-phospholipid complex. Br J Haemarol. 1973;24:391-400.
8. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:64-73.
9. Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
10. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or UFH. N Engl J Med. 1995;332:1330-1335.
11. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108:258S-275S.
12. Vitoux JF, Mathieu JF, Roncato M, Fiessinger JN, Aiach M. Heparin associated thrombocytopenia: treatment with low molecular weight heparin. Thromb Haemost. 1986;55:37-39.
13. Chong BH, Ismail F, Cade J, Gallua AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a low molecular weight heparinoid. ORG 10172. Blood. 1989;73:1592-1596.
14. Magnani H. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost. 1993; 70:554-561.
15. Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JL, Baron AE, Barton PL. A prospective study of heparin-induced osteoporosts in pregnancy using bone densitometry. Am J Obstet Gynecol. 1994;170:862-869.
16. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11.
17. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 194 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168: 1265-1270.
18. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular-weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995;86:1368-1373.
19. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, Shaughnessy SG. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 1996;88:1314-1320.
20. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KH, Barrett JJ, Kakkar VV. Use of low molecular weight heparin in pregnancy. Thromb Haemost. 1992;68:652-656.
21. Rosenberg RD, Jordon RE, Favreau LV, Lam LH. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun. 1979;86:1319-1324.
22. Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem. 1986;261:15467-15473.
23. Andersson L-O. Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X: effect of heparin neutralization in plasma. Thromb Res. 1979;15:531-541.
24. Jordan RE, Favreau LV, Braswell EH, Rosenberg RD. Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem. 1982; 257:400-406.
25. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than UFH. Thromb Haemost. 1994;71:300-304.
26. Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, Sie P. Pharmacokinetic studies of standard UFH and low molecular weight heparins in the rabbit. Semin Thromb Hemost. 1988;14:18-27.
27. Caranobe C, Barret A, Gabaig AM, Dupouy D, Sie P, Boneu B. Disappearance of circulating anti-Xa activity after intravenous injection of unfractionated heparin and of low molecular weight heparin (CY216) in normal and nephrectomized rabbits. Thromb Res. 1985;40:129-133.
28. Palm M, Mattsson CH. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost. 1987;58:932-935.
29. Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, Petitou M, Sinay P. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin-binding sequence. Biochem J. 1981;197:599-609.
30. Choay J, Petitou M, Lormeau JC, Sinay P, Casu BJ, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983;116:492-499.
31. Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J. 1981;193:395-400.
32. Holmer E, Soderberg K, Bergqvist D, Lindahl U. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986;16(suppl 2):1-7.
33. Kuijer PMM, Prins MH, Buller HR. Low-molecular-weight heparins: treatment of venous thromboembolism. In: Sasahara AA, Loscalzo J, eds. Advances in Therapeutic Agents in Thrombosis and Thrombolysis. New York, NY: M Dekker Inc; 1997:129-147.
34. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott G, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982.
35. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J-P, Azarian R, Laurent M, Hirsch J-L, Ferrari E, Bosson J-L, Mottier D, Beau B, for the THESEE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
36. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low molecular weight heparin administered primarily at home with UFH administered in the hospital for proximal deep vein thrombosis. N Engl J Med. 1996;334:677-681.
37. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, D'Azemar P, Buller HR, for the TASMAN Study Group. Treatment of venous thrombosis with intravenous UFH administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
38. The COLUMBUS Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657-662.
39. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA. 1996;276:811-815.
40. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Caroca AM, Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995;26:313-318.
41. FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease: Fragmin During Instability in Coronary Artery Disease (FRISC) study group. Lancet. 1996;347:561-568.
42. Klein W, Buchwald A, Hillis S, Monrad S, Sanz G, Turpie AGG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low molecular weight heparin with UFH acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: the Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997;96: 61-68.
43. Cohen M, Demers C, Gurfinkel E, for the ESSENCE Trial. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
44. Handeland GF, Abildgaard U, Holm HA, Arnesen K-E. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1980;39:107-112.